HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,195,278 | -20.7% | 31,290 | -25.1% | 0.99% | -12.5% |
| Q2 2023 | $1,507,365 | -5.6% | 41,790 | 0.0% | 1.13% | -9.0% |
| Q1 2023 | $1,595,960 | -32.9% | 41,790 | 0.0% | 1.24% | -30.6% |
| Q4 2022 | $2,377,851 | +24.0% | 41,790 | -13.8% | 1.79% | +9.5% |
| Q3 2022 | $1,917,000 | -13.2% | 48,490 | -3.4% | 1.64% | -7.8% |
| Q2 2022 | $2,208,000 | +11.4% | 50,190 | +1.0% | 1.78% | +33.9% |
| Q1 2022 | $1,982,000 | -6.3% | 49,690 | -5.5% | 1.33% | -1.1% |
| Q4 2021 | $2,115,000 | -2.5% | 52,590 | -1.4% | 1.34% | -16.0% |
| Q3 2021 | $2,170,000 | -10.6% | 53,341 | -0.2% | 1.60% | -10.5% |
| Q2 2021 | $2,427,000 | +156.3% | 53,457 | +25.2% | 1.78% | +136.3% |
| Q1 2021 | $947,000 | +0.1% | 42,712 | +92.9% | 0.76% | -7.1% |
| Q4 2020 | $946,000 | +30.8% | 22,146 | -19.5% | 0.81% | +24.9% |
| Q3 2020 | $723,000 | +4152.9% | 27,515 | +4159.3% | 0.65% | +3326.3% |
| Q2 2020 | $17,000 | – | 646 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |